Medtronic reports first quarter fiscal 2026 financial results
1. Medtronic's Q1 FY26 revenue rose 8.4% to $8.6 billion. 2. Organic revenue growth of 4.8% reported, matching FY26 guidance. 3. Cardiac Ablation Solutions surged nearly 50% in revenue, especially in the US. 4. Medtronic raised its FY26 EPS guidance to $5.60-$5.66. 5. CMS proposed coverage for Symplicity Spyral™ for hypertension, impacting future sales.